Research Article
PPARG: A Promising Therapeutic Target in Breast Cancer and Regulation by Natural Drugs
Table 2
PPARG expression levels in ER+ and ER− BC patients in relation to clinicopathological characteristics.
| | Clinicopathological characteristics | High expression group | Low expression group | -Value |
| Status | ER+ | Alive | 364 | 343 | 0.041 | Dead | 40 | 60 | ER− | Alive | 97 | 99 | 0.754 | Dead | 22 | 19 | Age | ER+ | Mean (SD) | 58.2 (13) | 60.5 (13.5) | 0.015 | Median [Min, Max] | 58 [26, 90] | 61 [29, 90] | ER− | Mean (SD) | 56.1 (11.8) | 55.7 (12.9) | 0.789 | Median [Min, Max] | 55 [29, 85] | 54.5 [26, 90] | Gender | ER+ | Female | 399 | 396 | 0.768 | Male | 5 | 7 | ER− | Female | 119 | 118 | ≤0.001 | Male | 0 | 0 | pT-stage | ER+ | TX | 0 | 2 | 0.025 | T1 | 123 | 90 | T2 | 207 | 247 | T3 | 65 | 47 | T4 | 9 | 17 | ER− | TX | 0 | 1 | 0.982 | T1 | 29 | 25 | T2 | 72 | 77 | T3 | 13 | 10 | T4 | 5 | 5 | pN-stage | ER+ | NX | 6 | 10 | 0.182 | N0 | 181 | 175 | N1 | 139 | 146 | N2 | 39 | 51 | N3 | 39 | 21 | ER− | NX | 1 | 1 | 0.375 | N0 | 61 | 75 | N1 | 32 | 30 | N2 | 15 | 7 | N3 | 10 | 5 | pM-stage | ER+ | MX | 67 | 70 | 0.553 | M0 | 329 | 320 | M1 | 6 | 10 | ER− | MX | 15 | 10 | 0.571 | M0 | 101 | 106 | M1 | 2 | 2 | pTNM-stage | ER+ | X | 4 | 7 | 0.013 | I | 81 | 60 | II | 211 | 231 | III | 100 | 92 | IV | 6 | 9 | ER− | X | 0 | 1 | 0.292 | I | 19 | 16 | II | 65 | 82 | III | 31 | 15 | IV | 1 | 2 |
|
|